Centessa Pharmaceuticals plc (CNTA) Stock Score, Valuation & Financial Research
Centessa Pharmaceuticals plc is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 23/100.
Quick answer for CNTA
Centessa Pharmaceuticals plc currently has a Wall Street Score of 23/100. The stored market price is $40.5. Its financial score is 22/100. Its valuation score is 0/100. These figures are a research snapshot, not a buy or sell recommendation.
What Centessa Pharmaceuticals plc does
Centessa Pharmaceuticals plc operates as a clinical-stage pharmaceutical enterprise focused on discovering, developing, and ultimately providing therapeutic solutions to patients. The company's most advanced product candidates include Lixivaptan, a small molecule inhibitor of the vasopressin V2 receptor, which is currently undergoing Phase III clinical evaluation for treating autosomal dominant polycystic kidney disease. Additionally, SerpinPC, an activated protein C inhibitor, is progressing through Phase IIa clinical development for the management of hemophilia A and B. Centessa's pipeline also features several emerging assets in the clinical proof-of-concept stage. These comprise LB101 (a PD-L1xCD47 LockBody) and LB201 (a PD-L1xCD3 LockBody), both engineered to selectively activate potent CD47 and CD3 effector functions while minimizing systemic side effects. Another molecule, ZF874,
CNTA financial snapshot
- Wall Street Score:
- 23/100
- Current price:
- $40.5
- Market capitalization:
- $6.27B
- Revenue:
- $0
- Net income:
- $-250.6M
- Free cash flow:
- $-194.2M
- Cash:
- $62.4M
- Total debt:
- $7.4M
- EPS:
- -1.78
- Financial score:
- 22/100
- Valuation score:
- 0/100
- Revenue score:
- 0/100
What stands out
- Reported year-over-year revenue growth is -1.0%.
- Free cash flow is $-194.2M, showing cash burn in the current stored period.
- The balance sheet shows $62.4M of cash versus $7.4M of total debt, leaving more cash than debt.
- The current research record carries a missing revenue history warning, which should be reviewed alongside the score.
What the numbers mean
Its current valuation score is 0/100, which Wall Street Score classifies as weak within the model's valuation framework.
The financial score is 22/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-09-17.
How to research CNTA
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.